A new study conducted by The Harris Poll and Delic Holdings Corp found that 65% of affected Americans want access to psychedelics for... Study Finds 65% Of Americans With Mental Health Conditions Want Access To Psychedelics

A new study conducted by The Harris Poll and Delic Holdings Corp found that 65% of affected Americans want access to psychedelics for mental health.

Respondents who self-reported that they suffer from a mental health condition say that psychedelic medicine including ketamine, psilocybin mushrooms, and MDMA, should be made available to patients with treatment-resistant anxiety, depression, or PTSD.

“The pandemic has skyrocketed the need for psychedelic wellness,” says Delic CEO Matt Stang. “We’re at a tipping point where the data and science regarding psychedelic therapies have become undeniable in treating a variety of serious conditions.”

As it stands, ketamine is legal in the U.S. for medical use. Ketamine is an FDA-approved anesthetic and can be prescribed for a myriad of ailments in a regulated setting by licensed clinicians. Psilocybin, like cannabis, is still considered a Schedule 1 drug in the eyes of the federal government. Therefore, its sale and use is illegal, despite some states and cities that have begun to decriminalize mushrooms. Beginning in 2019, psilocybin has been decriminalized in Denver, Oregon, and Santa Cruz. The state of California even has a measure on the 2022 ballot that would decriminalize psychedelic medicine in the state.
Read More

MJ Shareholders avatar

MJ Shareholders

MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers




( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )